Safety and efficacy of combination immunotherapy with nivolumab and ipilimumab for elderly lung cancer patients: a cohort study

Safety and efficacy of combination immunotherapy with nivolumab and ipilimumab for elderly lung cancer patients: a cohort study - Safety and efficacy of combination immunotherapy with nivolumab and ipilimumab for elderly lung cancer patients: a cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046353

Enrollment

Registered

2021-12-12

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced or recurrent non-small cell lung cancer patients who receive combination immunotherapy with nivolumab and ipilimumab

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
overall response rate, incidence of adverse events	—

Secondary

Measure	Time frame
duration of treatment	—

Countries

Japan

Contacts

Public ContactTakuma Imakita

National Hospital Organization Kyoto Medical Center Division of Respiratory Medicine

imakita-kyt@umin.ac.jp0756419161

Outcome results